NO911854L - Fremgangsmaate for fremstilling av peptid-derivater. - Google Patents

Fremgangsmaate for fremstilling av peptid-derivater.

Info

Publication number
NO911854L
NO911854L NO91911854A NO911854A NO911854L NO 911854 L NO911854 L NO 911854L NO 91911854 A NO91911854 A NO 91911854A NO 911854 A NO911854 A NO 911854A NO 911854 L NO911854 L NO 911854L
Authority
NO
Norway
Prior art keywords
alkyl
hydrogen
optionally substituted
con
carboxy
Prior art date
Application number
NO91911854A
Other languages
English (en)
Other versions
NO911854D0 (no
Inventor
Keiji Hemmi
Masahiro Neya
Naoki Fukami
Masashi Hashimoto
Hirokazu Tanaka
Natsuko Kayakiri
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO911854(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909010740A external-priority patent/GB9010740D0/en
Priority claimed from GB909026254A external-priority patent/GB9026254D0/en
Priority claimed from GB919104064A external-priority patent/GB9104064D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO911854D0 publication Critical patent/NO911854D0/no
Publication of NO911854L publication Critical patent/NO911854L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0217—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -C(=O)-C-N-C(=O)-N-C-C(=O)-
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Det beskrives en fremgangsmåte for fremstilling av peptid- forbindelse med formel (I): -'14 R" RJ R4 CON'' \CON^ \R5 R6 hvor Ri er hydrogen eller acyl, R2 er lavere alkyl, eventuelt substituert ar(lavere)alkyl, cyklo(lavere)alkyl(lavere)alkyl eller eventuelt substituert heterocyklisk(lavere)alkyl, R3 er eventuelt substituert heterocyklisk(lavere)alkyl eller eventuelt substituert ar(lavere)alkyl, R" er hydrogen, eller eventuelt substituert lavere alkyl, R5 er karboksy, beskyttet karboksy, karboksy(lavere)alkyl eller beskyttet karboksyflavere)alkyl, R6 er hydrogen eller eventuelt substituert lavere alkyl, R7 er hydrogen eller lavere alkyl, og A er -O-, -NH-, lavere alkylimino eller lavere alkylen, forutsatt at når R* er (S)-isobutyl, R3 N-(diklorbenzyl- oksykarbonyl)indol-3-ylmetyl, R" er metyl, R5 er metoksykarbonyl, R6 er hydrogen, R7 er hydrogen og A er -NH-, da har den partielle formel ,,3 R3 , den absolutte konfigurasjon - -CON ^CON- eller et salt derav. Forbindelsene kan finne anvendelse ved behandling og forebyggelse av endothelin-medierte sykdommer, så som hypertensjon og lignende.
NO91911854A 1990-05-14 1991-05-13 Fremgangsmaate for fremstilling av peptid-derivater. NO911854L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909010740A GB9010740D0 (en) 1990-05-14 1990-05-14 Peptide compounds and their preparation
GB909026254A GB9026254D0 (en) 1990-12-03 1990-12-03 Peptide compound and its preparation
GB919104064A GB9104064D0 (en) 1991-02-27 1991-02-27 Peptide compound and its preparation

Publications (2)

Publication Number Publication Date
NO911854D0 NO911854D0 (no) 1991-05-13
NO911854L true NO911854L (no) 1991-11-15

Family

ID=27265085

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91911854A NO911854L (no) 1990-05-14 1991-05-13 Fremgangsmaate for fremstilling av peptid-derivater.

Country Status (14)

Country Link
US (1) US5284828A (no)
EP (1) EP0457195B1 (no)
JP (1) JPH04244097A (no)
KR (1) KR910020030A (no)
CN (1) CN1057269A (no)
AT (1) ATE165100T1 (no)
CA (1) CA2042442A1 (no)
DE (1) DE69129248T2 (no)
FI (1) FI912328A (no)
HU (2) HUT57233A (no)
IE (1) IE911620A1 (no)
NO (1) NO911854L (no)
PT (1) PT97638B (no)
RU (1) RU2092491C1 (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5430022A (en) * 1990-05-14 1995-07-04 Fujisawa Pharmaceutical Co., Ltd. Peptide compound and its preparation
US5614498A (en) * 1990-06-07 1997-03-25 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
CA2043741C (en) * 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
US5496928A (en) * 1990-06-07 1996-03-05 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
GB9123967D0 (en) * 1991-11-12 1992-01-02 Fujisawa Pharmaceutical Co New compound and its preparation
TW217417B (no) * 1991-12-04 1993-12-11 Manyu Seiyaku Kk
DE69232771T2 (de) * 1991-12-27 2003-01-23 Kyowa Hakko Kogyo K.K., Tokio/Tokyo Peptide als antagonisten von endothelin
US5614497A (en) * 1991-12-27 1997-03-25 Takeda Chemical Industries, Ltd. Peptide, production and use thereof
WO1993023404A1 (en) * 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
US5922681A (en) * 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US5352800A (en) * 1993-03-11 1994-10-04 Merck & Co., Inc. Process for the production of a novel endothelin antagonist
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5374638A (en) * 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
CA2121724A1 (en) 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
GB9313330D0 (en) * 1993-06-28 1993-08-11 Fujisawa Pharmaceutical Co New compound and its preparation
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
US5780498A (en) * 1993-11-01 1998-07-14 Ciba-Geigy Japan Limited Endothelin receptor antagonists
JPH09510720A (ja) * 1994-03-28 1997-10-28 日本チバガイギー株式会社 エンドセリンレセプターのアンタゴニスト
US5830868A (en) * 1994-09-13 1998-11-03 Warner-Lambert Company Substituted DI- and tripeptide inhibitors of protein: farnesyl transferase
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5977075A (en) * 1995-04-21 1999-11-02 Novartis Ag N-aroylamino acid amides as endothelin inhibitors
CA2229263A1 (en) * 1995-09-26 1997-04-03 Toshifumi Watanabe Peptide derivatives, their production and use
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
IL131318A (en) 1997-04-28 2004-08-31 Encysive Pharmaceuticals Inc Pharmaceutically acceptable salts of sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
ATE315931T1 (de) * 1997-06-23 2006-02-15 Cellegy Pharma Inc Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
US6998445B2 (en) * 1998-03-26 2006-02-14 Acushnet Company Low compression, resilient golf balls with rubber core
AU4572999A (en) * 1998-06-18 2000-01-05 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
US7115664B2 (en) * 2000-03-16 2006-10-03 Sepracor Inc. Peptidomimetic ligands for cellular receptors and ion channels
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
ATE447955T1 (de) * 2001-08-24 2009-11-15 Univ Yale Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ATE495752T1 (de) 2005-07-19 2011-02-15 Population Council Inc Verfahren und zusammensetzungen zur notfallbedingten verhütung mithilfe von endothelin-rezeptor-antagonisten
WO2012028745A1 (en) 2010-09-03 2012-03-08 Pharmaterials Limited Pharmaceutical composition suitable for use in a dry powder inhaler
MY172013A (en) 2011-10-26 2019-11-12 Allergan Inc Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
KR102313757B1 (ko) * 2013-07-16 2021-10-18 알러간, 인코포레이티드 펩타이드 수용체 조절제로서의 n-우레아 치환된 아미노산의 유도체
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
EP4308170A1 (en) 2021-03-18 2024-01-24 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1049404B (it) * 1975-04-09 1981-01-20 Zambeletti Spa L Tripeptidi loro esteri ed amidi ad attivita antiulcera
US4127534A (en) * 1977-06-16 1978-11-28 Coy David Howard Novel tripeptides, intermediates therefor and pharmaceutical compositions and methods employing said tripeptides
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
CA1175810A (en) * 1979-03-30 1984-10-09 Frank A. Momany Synthetic peptides having pituitary growth hormone releasing activity
GB8430255D0 (en) * 1984-11-30 1985-01-09 Erba Farmitalia Biologically active oligopeptides
US5187156A (en) * 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
CA2043741C (en) * 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives

Also Published As

Publication number Publication date
DE69129248T2 (de) 1998-08-06
AU7644691A (en) 1991-11-14
DE69129248D1 (de) 1998-05-20
KR910020030A (ko) 1991-12-19
RU2092491C1 (ru) 1997-10-10
AU644648B2 (en) 1993-12-16
NO911854D0 (no) 1991-05-13
EP0457195A2 (en) 1991-11-21
PT97638B (pt) 1998-08-31
HU211904A9 (en) 1996-01-29
EP0457195B1 (en) 1998-04-15
EP0457195A3 (en) 1992-11-19
IE911620A1 (en) 1991-11-20
PT97638A (pt) 1992-02-28
FI912328A (fi) 1991-11-15
HUT57233A (en) 1991-11-28
CA2042442A1 (en) 1991-11-15
JPH04244097A (ja) 1992-09-01
US5284828A (en) 1994-02-08
CN1057269A (zh) 1991-12-25
FI912328A0 (fi) 1991-05-13
ATE165100T1 (de) 1998-05-15

Similar Documents

Publication Publication Date Title
NO911854L (no) Fremgangsmaate for fremstilling av peptid-derivater.
MX9401408A (es) Nuevos derivados heterociclicos.
DE69327541D1 (en) 4-arylmethyloxymethyl piperidine als tachykinin antagonisten
YU9301A (sh) Peptidi kao inhibitori hepatitisa c
DE69315079D1 (de) Beta-aminoalkyl und beta-n-peptidylaminoalkylborsäure
CA2078790A1 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
DK0736018T3 (da) 4,5-Diaryloxazolderivater
GB9602029D0 (en) New heterocyclic compounds
DE69433984D1 (de) Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d
ES2091359T3 (es) Nuevo compuesto peptidico y un procedimiento para su preparacion.
ATE254121T1 (de) Heterocyclische verbindungen als bradykinin antagonisten
NO20031671L (no) Dioksolananaloger for forbedret intercellulaer avlevering
FI913614A (fi) Menetelmä terapeuttisesti käyttökelpoisten N-sulfonyyli-indoliinijohdannaisten valmistamiseksi
ES2141827T3 (es) Peptidos que tienen actividad antagonista de endotelina, su preparacion y composiciones farmaceuticas de los mismos.
NO973340L (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av fedme
SE9603285D0 (sv) New compounds
ATE137764T1 (de) Vasoaktive derivate des vasotocins
PT827500E (pt) Derivados de (2-morfolinilmetil)benzamida
FI930166A (fi) Nya salter av dialkylaminoalkyl-26-sulfonylpristinamycin iib-derivat
WO2001007468A3 (en) Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
NO962809L (no) Fremgangsmåte for fremstilling av N-substituerte 4-ketoprolinderivater